|4th December 2020||Bros. Advisors Lp Baker||1,386,033||Open or private sale||$220.50||$305,620,276.50|
|4th December 2020||Bros. Advisors Lp Baker||125,513||Open or private sale||$220.50||$27,675,616.50|
|20th November 2020||Jason Ehrlich||981||Open or private sale||$138.56||$135,927.36|
|20th November 2020||Jason Ehrlich||57||Open or private sale||$140.88||$8,029.88|
|20th November 2020||Jason Ehrlich||2,134||Open or private sale||$139.39||$297,453.99|
|20th November 2020||Jason Ehrlich||400||Open or private sale||$137.27||$54,906.80|
|20th November 2020||Jason Ehrlich||2,614||Open or private sale||$139.96||$365,865.90|
|20th November 2020||Jason Ehrlich||505||Open or private sale||$133.71||$67,525.07|
|20th November 2020||Jason Ehrlich||259||Open or private sale||$134.72||$34,892.22|
|20th November 2020||Jason Ehrlich||6,950||Exercise of derivative||$10.29||$71,515.50|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.